## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AMG/

Sheet <u>1</u> of <u>13</u>

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304	
by Ap	losure Statement plicant	Applicant Naoki Kimura <i>et al</i> .		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643	

			U.S. Pate	ent Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	11/910,117	8/28/2007	Igawa et al.			
	2	12/307,042	12/30/2008	Kimura et al.			
	3	5,837,242	11/1998	Holliger et al.			
	4	5,840,344	11/24/1998	Fukushima			
	5	5,885,574	03/23/1999	Elliott			
	6	6,126,980	10/3/2000	Smith et al.			
	7	6,579,692	06/17/2003	Fukushima			
	8	6,719,972	04/13/2004	Gribben et al.			
	9	6,759,043	07/06/2004	Fukushima			
	10	2003/0147894	08/07/2003	Fukushima et al.			
	11	2003/0157100	08/2003	Fukushima et al.		:	
	12	2003/0157577	08/2003	Fukushima et al.			
	13	2003/0202975	10/2003	Tedder			
	14	2003/0211108	11/2003	Fukushima et al.			
	15	2004/0001828	1/1/2004	Tuscano et al.			
	16	2004/0073013	04/2004	Fukushima et al.			
	17	2005/0214278	9/29/2005	Kakuta et al.			
	18	2005/0267222	12/1/2005	Iwata et al.			
	19	2009/0028854	01/29/2009	Igawa <i>et al</i> .			
	20	2009/0117097	5/7/2009	Igawa <i>et al</i> .			

	Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Transla	tion	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No	
	21	CA 2272245	05/28/1998	Canada					
	22	EP 437 622	07/24/1991	Europe					
	23	EP 0 721 015	07/10/1996	Europe					
	24	EP 1 035 132	09/13/2000	Europe					

Examiner Signature /Anne M. Gussow/	Date Considered 09/01/2009			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Sheet <u>2</u> of <u>13</u>

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304	
Information Discl by App	olicant	Applicant Naoki Kimura <i>et al</i> .		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643	

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Transla	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	25	EP 0562125	09/29/1993	Europe				
	26	EP 1 396 500	03/10/2004	Europe				
	27	EP 1 262 548	8/10/2008	Europe				
	28	JP 3-41033	02/21/1991	Japan			Abstract only	
	29	JP 7236475	9/12/1995	Japan			Abstract only	
	30	JP 11-092500	04/06/1999	Japan			Abstract only	
	31	JP 2000-95800	04/04/2000	Japan			Abstract only	
	32	JP 2004-292455	10/21/2004	Japan			Abstract only	
	33	WO 91/16928	11/14/1991	WIPO				
	34	WO 92/19759	11/12/1992	WIPO			English abstract	
	35	WO 93/06862	4/15/1993	WIPO			English abstract	
	36	WO 94/13806	06/23/1994	WIPO				
	37	WO 96/36360	11/21/1996	WIPO				
	38	WO 97/01633	1/16/1997	WIPO				
	39	WO 97/32601	9/12/1997	WIPO			English abstract	
	40	WO 98/22136	5/28/1998	WIPO			English abstract	
	41	WO 98/44001	08/10/1998	WIPO				
	42	WO 99/17364	04/08/1999	WIPO				
	43	WO00/53634	09/14/2000	WIPO			English abstract	
	44	WO00/75191	12/14/2000	WIPO				
	45	WO01/77342	10/18/2001	WIPO				
	46	WO02/094880	11/28/2002	WIPO			English abstract	
	47	WO 02/096457	12/05/2002	WIPO				
	48	WO 02/097033	12/05/2002	WIPO				

09/01/2009					
03/01/2003					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304	
Information Discle by App	licant	Applicant Naoki Kimura <i>et al</i> .		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643	

	Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Transla	tion	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No	
	49	WO 03/086324	10/23/2003	WIPO					
	50	WO 04/037293	5/6/2004	WIPO			English abstract		
	51	WO 2006/123724	11/23/2006	WIPO			English abstract		

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	52	AVENT et al., "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific," <i>Biochem. J.</i> , 251:499-505 (1988)
	53	BARTLEY <i>et al.</i> , "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," <i>Cell</i> , 77:1117-1124 (1994)
	54	BAZIL et al., "Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes," Blood, 86:502-511 (1995)
	55	BAZZONI et al., "Chimeric tumor necrosis factor receptors with constitutive signaling activity," Proc. Natl. Acad. Sci. USA, 92(12):5376-5580 (1995)
	56	BERGER et al., "Inhibition of intractable nucleases with ribonucleoside-vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes," <i>Biochemistry</i> , 18(23):5143-5149 (1979)
	57	BODMER et al., "TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8," Nat. Cell Biol., 2:241-243 (2000)
	58	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science, 247:1306-1310 (1990)
	59	BROWN <i>et al.</i> , "Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins," <i>J. Cell Biology</i> , 111(6 Pt 1):2785-2794 (1990)
	60	BROWN et al., "Integrin-associated protein (CD47) and its ligands," Trends Cell Biology, 11(3):130-135 (2001)
	61	BUCHSBAUM et al., "Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model," Clin. Cancer Res., 9:3731-3741 (2003)
	62	BURTHEM et al., "Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins," Blood, 84(3):873-882 (1994)
	63	CALDAS et al., "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," Mol. Immunol., 39:941-952 (2003)
	64	CARPENTER et al., "Rational design of stable lyophilized protein formulations: some practical advice," Pharmaceutical Research, 14(8):969-975 (1997)
	65	CARPENTER et al., "Rational design of stable lyophilized protein formulations: theory and practice," <i>Pharma Biotechnol.</i> , 13:109-133 (2001)

Examiner Signature	Date Considered					
/Anne M. Gussow/	09/01/2009					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304	
Information Discl by App	olicant	Applicant Naoki Kimura et al.		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643	

		ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
minai	<u> </u>	CHIEN et al., "Significant structural and functional change of an antigen-binding site by a distant
	66	amino acid substitution: Proposal of a structural mechanism," <i>Proc. Nat. Acad. Sci. USA</i> , 86:5532-5536 (1989)
	67	CHIRGWIN et al., "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," Biochemistry, 18(24):5294-5299 (1979)
	68	CHUNTHARAPAI et al. "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," J. Immunol., 166:4891-4898 (2001)
	69	CLELAND et al., "A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody," <i>Journal of Pharmaceutical Sciences</i> , 90(3):310-321 (2001)
	70	COCHLOVIUS <i>et al.</i> , "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 x CD19 Tandem Diabody and CD28 Costimulation," <i>Cancer Res.</i> , 60:4336-4341 (2000)
	71	COOPER et al., "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," Proc. Natl. Acad. Sci. USA, 92:3978-3982 (1995)
	72	DANIEL et al., "Pathway of apoptosis induced in Jurkat T Lymphoblasts by anti-HLA Class I antibodies," <i>Human Immunology</i> , 65(3):189-199 (2004)
	73	DE LEON et al., "High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study," BMC Cancer, 9(48):1-9 (2009)
	74	DEGLI-ESPOSTI et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," J. Exp. Med., 186:1165-1170 (1997)
	75	DE SAUVAGE et al., "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," Nature, 369:533-538 (1994)
	76	DESPLANCQ et al., "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," Protein Engineering, 7(8):1027-1033 (1994)
	77	DE ST. GROTH et al., "Production of Monoclonal Antibodies: Strategy and Tactics," Journal of Immunological Methods, 35:1-21 (1980)
	78	DILLMAN, "Monoclonal antibodies for treating cancer," Ann. Int. Med., 11(7):592-603 (1989)
	79	DORAI et al., "Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains," <i>Biotechnology</i> , 12(9):890-897 (1994)
	80	EMERY et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," J. Biol. Chem., 273: 14363-14367 (1998)
	81	FELGENHAUER et al. "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," Nucleic Acids Research, 18(16):4927 (1990)
	82	FROKJAER <i>et al.</i> , "Protein drug stability: a formulation challenge," Nature Rev Drug Discov. 4:298-306 (2005)
	83	FUJIMOTO et al., "50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets," Blood, 86(6):2174-2182 (1995)
	84	FUKUSHIMA et al., "Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor," Blood, 80(8):1914-1922 (1992)

Examiner Signature	Date Considered		
/Anne M. Gussow/	09/01/2009		
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Discl	licant	Applicant Naoki Kimura <i>et al</i> .	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
	85	FUKUSHIMA et al., "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," Blood, 94(10):479A (1999)		
	86	GALFRE et al., "Preparation of monoclonal antibodies: strategies and procedures," Methods in Enzymology, 73:3-46 (1981)		
	87	GALFRE et al., "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG,"		
		Nature, 277:131-133 (1979)		
	88	GARCIA-GONZALEZ et al., "Purification of murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation," Journal of Immunological Methods, 111:17-23 (1988)		
		GIUSTI et al., "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA		
	89	autoantibody is due to a single base change in its heavy chain variable region," <i>Proc. Natl. Acad. Sci. USA</i> , 84:2926-2930 (1987)		
	90	GODING, "Monoclonal Antibodies: Principles and Practice," <i>Academic Press</i> , second Ed., 125:129 (1986)		
	91	GOMBOTZ et al., "The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone)," <i>Pharmaceutical Research</i> , 11(5):624-632 (1994)		
	92	GREENSPAN et at., "Defining epitopes: It's not as easy as it seems," <i>Nature Biotechnology</i> , 17:936-937 (1999)		
	93	GRELL et al., "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis," Lymphokine and Cytokine Research, 12(3):143-148 (1993)		
	94	GRIFFITH et al., "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," J. Immunol., 162:2597-2605 (1999)		
	95	GÜSSOW and SEEMANN, "Humanization of Monoclonal Antibodies," <i>Methods in Enzymology</i> , 203:99-121 (1991)		
	96	HOLLIGER el at., "Specific Killing of Lymphoma Cells by Cytotoxic T-Cells Mediated by a Bispecific Diabody," <i>Protein Engineering</i> , 9(3):299-305 (1996)		
	97	HOPP et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> , 6:1204-1210 (1988)		
	98	HORAN <i>et al.</i> , "Dimerization of the extracellular domain of granuloycte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes," <i>Biochemistry</i> , 35:4886-4896 (1996)		
	99	HUSTON et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia Coli," Proc. Natl. Acad. Sci. USA, 85:5879-5883 (1988)		
	100	ITOH et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," Cell, 66:233-243 (1991)		
	101	JIANG et al., "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," J. Biol. Chem., 280(6):4656-4662 (2005)		
	102	JONES et al., "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions,"  Biotechnology, 9:88-89 (1991)		
	103	KEARNEY, et al., "A New Mouse Myeloma Cell Line That Has Lost immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," The Journal of Immunology, 123(4):1548-1550 (1979)		

Examiner Signature	Date Considered		
· ·			
/Anne M. Gussow/	09/01/2009		
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with			
next communication to applicant			

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Discl by App		Applicant Naoki Kimura <i>et al.</i>	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
	104	KEEN et al., "The use of serum-free medium for the production of functionally active humanized monoclonal antibody from NSO mouse myeloma cells engineered using glutamine synthetase as a selectable marker," Cytotechnology, 18(3):207-217 (Abstract) (1994)		
	105	KIPRIYANOV et al., "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells," In. J. Cancer, 77:763-772 (1998)		
	106	KOHLER, et al., "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," Eur. J. Immunol., 6:511-519 (1976)		
	107	KORTT et al., "Recombinant anti-sialidase single-chain variable fragment antibody: Characterization, formation of dimmer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex," Eur. J. Biochem., 221:151-157 (1994)		
	108	KORTT <i>et al.</i> , "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten- residue linkers form dimmers and with zero-residue linker a trimer," <i>Protein Engineering</i> , 10(4):423433 (1997)		
	109	KOZAK, M., "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987)		
	110	LARRICK, et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," <i>Biotechnology</i> , 7:934-938 (1989)		
	111	LAW et al., "Observations On The Effect Of A Folic-Acid Anatagonist On Transplantable Lymphoid Leukemias In Mice," Journal of the National Cancer Institute, 10:179-193 (1949)		
	112	LE GALL et al., "Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody," Protein Engineering Design & Selection, 17(4):357-366 (2004)		
	113	LEE et al., "Reversible dimer formation and stability of the anti-tumour single chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FR-IR spectroscopy," J. Mol. Biol., 320:107-127 (2002)		
	114	LEI et al., "Characterization of the Erwinia Carotovora pelB Gene and Its Product Pectate Lyase,"  Journal of Bacteriology, 4379-4383 (1987)		
	115	LINDBERG et al., "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in α <sub>ν</sub> β <sub>3</sub> -Dependent Ligand Binding," <i>The Journal of Cell Biology</i> , 123(2):485-496, The Rockefeller University Press (1993)		
	116	LINDBERG et al., "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," J. Biol. Chem., 269:1567-1570 (1994)		
	117	MARGULIES et al., "Somatic Cell Hybridization of Mouse Myeloma Cells," Cell, 8:405-415 (1976)		
	118	MARIUZZA et al., "The structural basis of antigen-antibody recognition," Ann. Rev. Biophys. Biophys. Chem., 16:139-159 (1987)		
	119	MARIUZZA et al., "The Structural Basis of Antigen-Antibody Recognition," Ann. Rev. Biophys. Chem., 16:139-159 (1987)		
	120	MARSTERS et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain," Curr. Biol., 7:1003-1006 (1997)		

Examiner Signature	Date Considered			
/Anne M. Gussow/	09/01/2009			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				
next communication to applicant.				

 Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304	
by Ap	closure Statement oplicant	Applicant Naoki Kimura <i>et al</i> .		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643	

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Desig.			
Initial	ID	Document	
	121	MARTSEV et al., "Antiferritin single-chain antibody: a functional protein with incomplete folding?" FEBS Letters, 441:458-462 (1998)	
	122	MATEO et at al., "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," FASEB Journal, 12(5):A1082 (1998)	
		MAWBY et al., "Isolation and characterization of CD47 glycoprotein: a multispanning membrane	
	123		
	124	METHIA et al., "Oligodeoxynucleotides Antisense to the Proto-Oncogene c-Mpl Specifically Inhibit In Vitro Megakaryocytopoiesis," Blood, 82(5):1395-1401 (1993)	
	125	MILILI et al., "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of Bona Fide Heavy Chains," Eur. J. Immunol., 26:63-69 (1996)	
	126	MIZISHIMA et al. "DEE BOS a Dayyorful Mammalian Ermandian Victor," No. 1 : 1	
		MOORE et al., "Kinetics and thermodynamics of dimer formation and dissociation for a	
	127	recombinant humanized monoclonal antibody to vascular endothelial growth factor," <i>Biochemistry</i> , 38:13960-13967 (1999)	
	128	MORI <i>et al.</i> , "Human normal hepatocytes are suspectible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2," <i>Cell Death and Differentiation</i> , 11:203-207 (2004)	
	129	MULLIGAN et al., "Synthesis of Rabbit \( \beta\)-Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 \( \beta\)-Globin Recombinant Genome," Nature, 277:108-114 (1979)	
	130	NAKAYAMA <i>et al.</i> , "Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression," <i>Journal of Molecular Medicine</i> , 83:316-320 (2005)	
	131	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure Prediction, Merz, Jr. et al. Editors, Birkhauser Boston, 433-506 (1994)	
	132	O'BRIEN et al., "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," Biochim. Soc. Trans., 14(6):1021-1023 (1986)	
	133	OHTSUKA et al., "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway," Oncogene, 22:2034-2044 (2003)	
	134	PAN et al., "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," Science, 277:815-818 (1997)	
	135	PAN et al., "The Receptor for the Cytotoxic Ligand TRAIL," Science, 276:111-113 (1997)	
136 PAUL, Fundamental Immunology, Raven Press, NY, Chapter 8, p. 242 (1993)  137 PETTERSON et al., "CD47 Signals T Cell Death," J. Immunol., 7031-7040 (1999)			
		PETTERSON et al., "CD47 Signals T Cell Death," J. Immunol., 7031-7040 (1999)	
	138	PETTERSON, "CD47 and death signaling in the immune system," Apoptosis, 5:299-306 (2000)	
	139	REINHOLD et al., "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," J. Cell Science, 108:3419-3425 (1995)	
	140	RIECHMANN et al., "Reshaping Human Antibodies for Therapy," Nature, 332:323-327 (1988)	

Examiner Signature	Date Considered	
/Anne M. Gussow/	09/01/2009	
EXAMINER: Initials citation considered. Draw line through citation	on if not in conformance and not considered. Include copy of this form with	

Substitute Form PTO-1449  (Modified)  U.S. Department of Comme Patent and Trademark Of			
by Ap	losure Statement plicant	Applicant Naoki Kimura <i>et al</i> .	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
		REITER et al., "Engineering interchain disulfide bonds into conserved framework regions of Fv
	141	
· · · · · · · · · · · · · · · · · · ·		stabilized Fv," Protein Engineering, 7(5):697-704 (1994)
	142	REITER et al., "Stabilization of the Fv Fragments in Recombinant Immunotoxins by Disulfide
	172	Bonds Engineered into Conserved Framework Regions," Biochemistry, 33:5451-5459 (1994)
	143	ROUE et al. "Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS
	143	production in the absence of cytochrome c and AIF release," <i>Biochimie.</i> , 85:741-746 (2003)
		ROZSNYAY et al., "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response
	144	
		(1993)
		SATO et al., "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell
	145	Growth," Cancer Research, 53:851-856 (1993)
		SCHICKEL, et al., "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping,
	146	
	110	(2002)
		SCHWARTZ et al., "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated
	147	Calcium Entry in endothelial Cells," J. Biol. Chem., 268(27):19931-19934 (1993)
		SCHMIDT et al., "A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF
	148	receptor," Int. J. Cancer, 65(4):538-546 (1996)
	149	SHARMA et al., "Study of IgM aggregation in serum of patients with macroglobulinemia," Clin
		Chem Lab Med, 38(8):759-764 (2000)
	150	SHERIDAN et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy
		Receptors," Science, 277:818-821 (1997)
	151	SHIGETA et al., "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens,"
		Clin. Exp. Immunol., 42:458-462 (1980)
	152	SHULMAN et al., "A better cell line for making hybridomas secreting specific antibodies," Nature,
		276:269-270 (1978)
	153	SOUYRI, M., "Mpl: from an acute myeloproliferative virus to the isolation of the long sought
		thrombopoietin," Seminars in Hematology, 35(3):222-231 (1998)
	154	SPAARGAREN et al., "Antibody-induced Dimerization Activates the Epidermal Growth Factor
		Receptor Tyrosine Kinase," The J. Biol. Chem., 266(3):1733-1739 (1981)
	155	STANCOVSKI et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the
	155	ERBB2 receptor on tumor growth," Proc. Natl. Acad. Sci. USA, 88:8691-8695 (1991)
İ	156	TROWBRIDGE, I.S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies
	130	Against Mouse Lymphocyte Surface Glycoprotein, T200," J. Exp. Med., 148:313-323 (1978)
	157	VAN GEELEN et al., "Differential modulation of the TRAIL receptors and the CD95 receptor in
	137	colon carcinoma cell lines," Br. J. Cancer, 89(2):363-373 (2003)
	150	VERMA et al., "Antibody engineering: Comparison of bacterial, yeast, insect and mammalian
	158	expression systems," Journal of Immunological Methods, 216:165-181 (1998)
	1.50	WALCZAK et al., "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL," EMBO J.,
	159	16:5386-5397 (1997)
		WANG et al., "Instability, stabilization, and formulation of liquid protein pharmaceuticals,"
	160	International Journal of Pharmaceutics, 185:129-188 (1999)

Examiner Signature /Anne M. Gussow/	Date Considered 09/01/2009	
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Discle by App		Applicant Naoki Kimura <i>et al</i> .	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643

Examiner	Desig.	ocuments (include Author, Title, Date, and Place of Publication)
Initial	Desig.	Document
miliai		WANG et al., "Lyophilization and development of solid protein pharmaceuticals," International
	161	Journal of Pharmaceutics, 203:1-60 (2000)
		WANG et al., "Protein aggregation and its inhibition in biopharmaceutics," International Journal of
	162	Pharmaceutics, 289:1-30 (2005)
	163	
		WILEV et al. "Identification and Characterization of a New Member of the TNE Family that
	164	Induces Apoptosis," Immunity, 3:673-682 (1995)
		WINKLER et al., "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-
	165	p24 (HIV-1) Antibody," J. Immunol., 265:4505-4514 (2000)
		XIE et al., "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering
	166	Through Identification of Agonist ScFv," Nature Biotechnology, 15(8):768-771 (1997)
		YANABU et al., "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein lb
	167	monoclonal antibody," <i>Blood</i> , 89(5):1590-1598 (1997)
	1.00	YARDEN et al., "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of
	168	intermolecular allosteric activation," Biochemistry, 26(5):1434-1442 (1987)
169		YELTON et al., "Fusion of Mouse Myeloma and Spleen Cells," Current Topics in Microbiology
		and Immunology, 81:1-7 (1978)
	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App	
170		No. 10/530,696, mailed October 19, 2006, 8 pages
	171	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2006, in U.S.
1/1		App. Ser. No. 10/530,696, filed November 16, 2006, 1 page
	172	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser.
1,72		No. 10/530,696, mailed December 21, 2006, 19 pages
	173	FISH & RICHARDSON P.C., Response to Office Action dated December 21, 2006 in U.S. App.
	1,0	Ser. No. 10/530,696, filed April 23, 2007, 16 pages
174		U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser.
	* ' '	No. 10/530,696, mailed August 8, 2007, 13 pages
	175	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser.
		No. 10/530,696, mailed November 26, 2007, 3 pages
ĺ	176	FISH & RICHARDSON P.C., Response to Office Action dated December 21, 2006 in U.S. App.
		Ser. No. 10/530,696, filed December 6, 2007, 12 pages
	177	U.S. EXAMINER ANNE GUSSOW, USPTO Advisory Action in U.S. App. Ser. No. 10/530,696,
		mailed December 14, 2007, 4 pages
l	178	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser.
		No. 10/530,696, mailed February 5, 2008, 9 pages
179	179	FISH & RICHARDSON, Response to Office Action dated February 5, 2008 in U.S. App. Ser.
		No. 10/530,696, filed August 5, 2008, 7 pages U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser.
	180	No. 10/530,696, mailed November 17, 2008, 18 pages
		FISH & RICHARDSON, Response to Office Action dated November 17, 2008 in U.S. App. Ser.
	181	No. 10/530,696, filed February 17, 2009, 14 pages
		JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2003/013063
	182	mailed November 18, 2003, 2 pages
L	aturo	munica November 10, 2005, 2 pages

Examiner Signature	Date Considered		
/Anne M. Gussow/	09/01/2009		
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with part communication to applicant.			

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Discl		Applicant Naoki Kimura <i>et al</i> .	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643

		ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Dogument
IIIIIIai	<u>טו</u>	Document Document
	183	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser.
		No. PCT/JP2003/013063, dated February 6, 2004, 4 pages
	184	EPO EXAMINER W. BERNHARDT, European Search Report for App. Ser.
	_ , ,	No. EP 03 75 1456, dated April 4, 2006, 2 pages
	185	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser.
	103	No. 10/530,696, mailed June 8, 2009, 10 pages
	186	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Restriction Requirement in U.S. App. Ser.
	100	No. 10/548,727, mailed April 12, 2007, 6 pages
	187	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated April 12, 2007 in U.S. App.
	107	Ser. No. 10/548,727, filed May 3, 2007, 1 page
	100	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser.
	188	No. 10/548,727, mailed August 3, 2007, 21 pages
	100	FISH & RICHARDSON P.C., Reply to Office Action dated August 3, 2007 in U.S. App. Ser.
	189	No. 10/548,727, filed January 15, 2008, 15 pages
		U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Final Office Action in U.S. App. Ser.
	190	No. 10/548,727, mailed April 29, 2008, 23 pages
		U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Advisory Action in U.S. App. Ser.
19		No. 10/548,727, mailed September 24, 2008, 6 pages
		U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser.
	192	No. 10/548,727, mailed January 28, 2009, 16 pages
		JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/003334
	193	mailed June 15, 2004, 3 pages
		JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser.
	194	No. PCT/JP2004/003334, dated May 2, 2005, 6 pages
		U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser.
	195	No. 10/550,934, mailed November 21, 2007, 7 pages
		FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 21, 2007 in
	196	U.S. App. Ser. No. 10/550,934, filed April 16, 2008, 2 pages
		U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser.
	197	
		No. 10/550,934, mailed June 12, 2008, 27 pages
	198	FISH & RICHARDSON P.C., Response to Office Action dated June 12, 2008 in U.S. App. Ser.
		No. 10/550,934, filed December 12, 2008, 45 pages
	199	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/550,934
		mailed March 16, 2009, 19 pages
	200	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/004696
		mailed July 27, 2004, 5 pages
	201	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser.
	201	No. PCT/JP2004/004696, dated February 9, 2005, 10 pages
	202	EPO EXAMINER N. FAVRE, European Search Report for App. Ser. No. EP 04 72 4770, dated
	202	March 31, 2006, 4 pages
	203	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser.
	203	No. 10/551,504, mailed June 27, 2008, 6 pages

Examiner Signature	Date Considered			
/Anne M. Gussow/	09/01/2009			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				
next communication to applicant.	· ·			

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Discl by App		Applicant Naoki Kimura <i>et al</i> .	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID ID	Document			
	204	FISH & RICHARDSON P.C., Response to Restriction Requirement dated June 27, 2008 in U.S.			
	201	App. Ser. No. 10/551,504, filed September 29, 2008, 13 pages			
	205	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser.			
	203	No. 10/551,504, mailed December 16, 2008, 5 pages			
	FISH & RICHARDSON P.C., Response to Restriction Requirement dated December 16				
	200	U.S. App. Ser. No. 10/551,504, filed December 23, 2008, 14 pages			
	207	U.S. EXAMINER LORRAINE SPECTOR, USPTO Non-Final Office Action in U.S. App. Ser.			
	207	No. 10/551,504, mailed April 15, 2009, 35 pages			
	208	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018506,			
	200	mailed March 22, 2005, 3 pages			
	209	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on			
	209	Patentability for App. Ser. No. PCT/JP2004/018506, 8 pages			
	210	EPO EXAMINER ROBERT RANKIN, European Search Report for App. Ser.			
	210	No. EP 04 82 0316, dated July 17, 2008, 3 pages			
	211	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499,			
	211	mailed January 18, 2005, 2 pages			
	212	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser.			
	212	No. PCT/JP2004/018499, dated January 26, 2006, 5 pages			
	213	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser.			
	213	No. 10/582,413, mailed January 4, 2008, 8 pages			
	214	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499,			
mailed January 18, 2005, 2 pages		mailed January 18, 2005, 2 pages			
	FISH & RICHARDSON P.C., Response to Restriction Requirement dated January 4, 20 App. Ser. No. 10/582,413, filed February 4, 2008, 2 pages				
	216	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser.			
}	210	No. 10/582,413, mailed March 31, 2008, 17 pages			
	217	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 31, 2008 in U.S. App.			
	217	Ser. No. 10/582,413, filed June 30, 2008, 20 pages			
	210	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser.			
ļ	218	No. 10/582,413, mailed June 30, 2008, 2 pages			
	210	U.S. EXAMINER BRADLEY DUFFY, USPTO Notice of Informal or Non-Responsive Amendment			
	219	in U.S. App. Ser. No. 10/582,413, mailed October 20, 2008, 3 pages			
	220	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser.			
	220	No. 10/582,413, mailed November 12, 2008, 4 pages			
		FISH & RICHARDSON P.C., Amendment in Reply to Notice of Informal or Non-Responsive			
	221	Amendment dated October 20, 2008 in U.S. App. Ser. No. 10/582,413, filed November 17, 2008,			
		10 pages			
	222	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser.			
	222	No. 10/582,413, mailed November 25, 2008, 4 pages			
	222	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser.			
	223	No. 10/582,413, mailed December 24, 2008, 4 pages			
	201	U.S. EXAMINER BRADLEY DUFFY, USPTO Restriction Requirement in U.S. App. Ser.			
}	224	No. 10/582,413, mailed March 11, 2009, 8 pages			
L		, , , , , , , , , , , , , , , , , , ,			

Examiner Signature	Date Considered		
/Anne M. Gussow/	09/01/2009		
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Discl by App	olicant	Applicant Naoki Kimura <i>et al</i> .	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	225	FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 11, 2009 in U.S.			
223		App. Ser. No. 10/582,413, filed April 8, 2009, 8 pages			
	226	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018493,			
	220	mailed March 22, 2005, 2 pages			
	227	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser.			
	221	No. PCT/JP2004/018493, dated December 20, 2005, 7 pages			
	228	EPO EXAMINER INGE KALSNER, European Search Report for App. Ser.			
	220	No. EP 04 82 0305, dated October 6, 2008, 3 pages			
	229	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/005152,			
	22)	mailed July 20, 2004, 2 pages			
	230	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser.			
	250	No. PCT/JP2004/005152, dated February 14, 2005, 6 pages			
	231	EPO EXAMINER WIEBKE BERNHARDT, European Search Report for App. Ser.			
	231	No. EP 04 72 6750, dated February 4, 2008, 3 pages			
	232	U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser.			
	232	No. 11/547,747, mailed June 1, 2009, 41 pages			
	233	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/306800,			
	233	mailed May 16, 2006, 4 pages			
	234	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on			
		Patentability for App. Ser. No. PCT/JP2006/306800, dated October 3, 2007, 6 pages			
	235	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/309890,			
	233	mailed July 18, 2006, 2 pages			
	236	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability			
		for App. Ser. No. PCT/JP2006/309890, dated November 19, 2007, 5 pages			
	237	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/311625,			
		mailed August 22, 2006, 2 pages			
	238	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on			
		Patentability for App. Ser. No. PCT/JP2006/311625, dated December 11, 2007, 4 pages			
ļ	239	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2007/063946,			
		mailed August 14, 2007, 7 pages			
	240	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on			
		Patentability for App. Ser. No. PCT/JP2007/063946, dated January 20, 2009, 10 pages			
	241	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser.			
		No. 10/582,654, mailed May 26, 2009, 9 pages			
	242	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Restriction Requirement in U.S. App. Ser.			
		No. 10/399,518, mailed November 25, 2005, 9 pages			
		FOLEY & LARDNER LLP, Response to Restriction Requirement dated November 25, 2005 in U.S.			
		App. Ser. No. 10/399,518, filed December 23, 2005, 3 pages			
	244	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser.			
		No. 10/399,518, mailed March 27, 2006, 38 pages			
	245	FOLEY & LARDNER LLP, Amendment in Reply to Action dated March 27, 2006 in U.S. App.			
		Ser. No. 10/399,518, filed September 26, 2006, 26 pages			

Examiner Signature	Date Considered					
/Anne M. Gussow/	09/01/2009					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with						
next communication to applicant.						

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
	losure Statement plicant	<sup>Applicant</sup> Naoki Kimura <i>et al</i> .	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 20, 2007	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
246		FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in		
		U.S. App. Ser. No. 10/399,518, filed October 11, 2006, 11 pages		
	247	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 13, 2006, 11 pages		
	248	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser.		
	2,70	No. 10/399,518, mailed December 28, 2006, 29 pages		
	249	FOLEY & LARDNER LLP, Amendment in Reply to Action dated December 28, 2006 in U.S. App.		
		Ser. No. 10/399,518, filed May 3, 2007, 22 pages		
	250	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser.		
		No. 10/399,518, mailed June 7, 2007, 13 pages		
	251	FOLEY & LARDNER LLP, Amendment in Reply to Action dated June 7, 2007 in U.S. App. Ser. No. 10/399,518, filed September 7, 2007, 9 pages		
		U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518,		
	252	mailed September 27, 2007, 5 pages		
	253	U.S. EXAMINER DAVID J. BLANCHARD, Interview Summary in U.S. App. Ser.		
		No. 10/399,518, mailed November 13, 2007, 3 pages		
	254	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser.		
		No. 10/399,518, mailed January 31, 2008, 14 pages		
	255	FOLEY & LARDNER LLP, Amendment in Reply to Action dated January 31, 2008 in U.S. App.		
		Ser. No. 10/399,518, filed April 30, 2008, 7 pages		
	256	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser.		
		No. 10/399,518, mailed August 4, 2008, 8 pages		
	257	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518,		
		mailed November 7, 2008, 4 pages		
	258	FOLEY & LARDNER LLP, Amendment in Reply to Action dated November 7, 2008 in U.S. App.		
		Ser. No. 10/399,518, filed October 23, 2008, 8 pages		
	259	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser.		
		No. 10/399,518, mailed February 17, 2009, 12 pages		
	260	FOLEY & LARDNER LLP, Amendment in Reply to Action dated February 17, 2009 in U.S. App.		
		Ser. No. 10/399,518, filed May 18, 2009, 26 pages		
	261	FISH & RICHARDSON P.C., Reply to Office Action dated January 28, 2009 in U.S. App. Ser. No.		
		10/548,727, filed June 26, 2009, 9 pages		
	262	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser.		
	- · <del>-</del>	No. 10/582,413, mailed June 25, 2009, 28 pages		

Examiner Signature	Date Considered			
/Anne M. Gussow/	09/01/2009			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				